Evidence map›Paper›PMID 22341593›Full record

ArticleAtherosclerosis2012

Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease.

Victor H Urbieta-Caceres, Xiang-Yang Zhu, Kyra L Jordan, Hui Tang, Kyle Textor, Amir Lerman, Lilach O Lerman

Abstract read
In one paragraph

Article in Atherosclerosis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. [Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. The metabolic syndrome induces early changes in the swine renal medullary mitochondria.Translational research : the journal of laboratory and clinical medicine · 2017
    Article
  10. Article
  11. Paradigm Shifts in Atherosclerotic Renovascular Disease: Where Are We Now?Journal of the American Society of Nephrology : JASN · 2015
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Victor H Urbieta-CaceresThe Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States.
Xiang-Yang Zhu
Kyra L Jordan
Hui Tang
Kyle Textor
Amir Lerman
Lilach O Lerman
WinnMed · USMayo Clinic · US

Funding

Tissue Oxygenation in Human Renovascular HypertensionP01HL085307 · NHLBI · MAYO CLINIC ROCHESTER · PI TEXTOR, STEPHEN C · 2007 to 2011
$10.4M
CT imaging for the assessment of kidney injury distal to renal artery stenosisR01DK073608 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2006 to 2015
$3.1M
CT Evaluation of the Myocardial Effects of Risk FactorsR01HL077131 · NHLBI · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2004 to 2013
$2.8M
EXTRAMURAL RES FACIL IMPROVEMENT PROG: POLYCYSTIC KIDNEY DISEASE, RENAL STUDIES,C06RR018898 · NCRR · MAYO CLINIC · PI BURNETT, JOHN C · 2004 to 2004
$2.3M
Autologous Progenitor Cells Delivery in Renovascular DiseaseR21DK077013 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2008 to 2009
$416k
NCRR NIH HHS C06 RR018898NCRR NIH HHS RR018898NHLBI NIH HHS HL-77131NHLBI NIH HHS P01 HL085307NHLBI NIH HHS P01HL-085307NHLBI NIH HHS R01 HL077131NIDDK NIH HHS DK-73608NIDDK NIH HHS DK77013NIDDK NIH HHS R01 DK073608NIDDK NIH HHS R21 DK077013
6 · The paper itself

Abstract

aimAtherosclerotic renovascular disease (ARVD) may impair renal function and increase cardiovascular morbidity and mortality, but the mechanism by which ARVD impacts cardiovascular function is unclear. We tested the hypothesis that preservation of renal function can reverse cardiac dysfunction in ARVD. METHODS AND

resultsEndothelial progenitor cells (EPC) were injected intra-renally (ARVD+EPC) after 6 weeks of swine ARVD (concurrent hypercholesterolemia and renovascular hypertension), and single-kidney function and myocardial blood-flow and microvascular permeability (MP) responses to adenosine were assessed using CT 4 weeks later. Myocardial microvascular density was evaluated by micro-CT. Inflammation and oxidative-stress were assessed in kidney venous and systemic blood samples. Normal and untreated ARVD pigs served as controls. Blood pressure was similarly increased in ARVD and ARVD+EPC. Compared to normal, ARVD showed lower glomerular filtration rate, elevated renal vein and systemic oxidized LDL (ox-LDL), aldosterone, uric acid, isoprostanes, transforming growth factor (TGF)-β, and interleukine-6. Renal vein ox-LDL and TGF-β showed a positive gradient across the stenotic kidney, indicating increased renal oxidative stress and fibrogenic activity. Furthermore, ARVD impaired myocardial blood-flow and MP response to adenosine, decreased microvascular density, and induced myocardial fibrosis. Improvement of renal function in ARVD+EPC decreased systemic aldosterone, inflammation, and oxidative stress, and improved myocardial microvascular integrity and density.

conclusionSelective improvement in renal function, which reduced renal and systemic oxidative stress and inflammation, preserved remote myocardial microvascular function and architecture, despite enduring hypertension. These findings underscore functionally important cardiorenal crosstalk possibly mediated by renal injury signals.

Indexed as

Coronary CirculationMicrocirculationStem Cell TransplantationAnimalsAtherosclerosisBiomarkersBlood PressureCapillary PermeabilityCardiac OutputCatheterizationCells, CulturedDiet, High-FatDisease Models, AnimalEndothelial CellsFibrosisGlomerular Filtration RateBiomarkersInflammation Mediators

Identifiers

PMID22341593
PMCPMC3637916
OpenAlexW2015856895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.